Salajegheh Faranak, Salajegheh Somayyeh, Nakhaie Mohsen, Farsiu Niloofar, Khoshnazar Seyedeh Mahdieh, Sinaei Reza, Farrokhnia Mehrdad, Torabiyan Soheila
Endocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Clin Diabetes Endocrinol. 2024 Aug 31;10(1):29. doi: 10.1186/s40842-024-00184-7.
Elevated blood glucose concentration, also known as hyperglycemia, has been identified as a significant factor influencing the prognosis of COVID-19, alongside the impact of the SARS-CoV-2 infection itself.
This research is a cross-sectional investigation that examined the relationship between COVID-19 and hyperglycemia in patients admitted to Afzalipour Hospital in Kerman, Iran, from July to September 2021. A standardized data sheet was used to capture demographic data (age, gender) and laboratory information (blood sugar, arterial blood oxygen saturation, and C-reactive protein (CRP)) upon admission.
The present research evaluated a total of 300 individuals diagnosed with COVID-19, with an average age of 50.19 ± 15.55 years. Among these patients, the majority were male, accounting for 51.67% of the total. Hyperglycemia was seen in 21.67% of patients, but less than 20% had new-onset diabetes. Individuals exhibiting hyperglycemia were typical of advanced age (P < 0.001). Furthermore, there was a slight but statistically significant association between advanced age and elevated blood glucose concentration (R = 0.254, P < 0.001). Gender had no significant impact on the occurrence of hyperglycemia (P = 0.199). There was no significant association between CRP levels and blood glucose concentration (P = 0.524) or the incidence of hyperglycemia (P = 0.473). Although there was no significant disparity in blood oxygen saturation between individuals with or without hyperglycemia (P = 0.06), higher blood glucose concentration was correlated with lower blood oxygen saturation (R = -0.151, P < 0.001).
Considering the correlation between blood glucose concentration, advanced age, and disease severity, it is recommended to carefully screen and monitor all COVID-19 patients for hyperglycemia and new-onset diabetes. Effective management of these complications could enhance the control of patients' overall prognosis and subsequent complications.
血糖浓度升高，也称为高血糖症，已被确定为影响新型冠状病毒肺炎（COVID-19）预后的一个重要因素，这与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染本身的影响并存。
本研究为横断面调查，研究了2021年7月至9月在伊朗克尔曼的阿夫扎利普尔医院住院的COVID-19患者与高血糖症之间的关系。采用标准化数据表收集入院时的人口统计学数据（年龄、性别）和实验室信息（血糖、动脉血氧饱和度和C反应蛋白（CRP））。
本研究共评估了300例确诊为COVID-19的患者，平均年龄为50.19±15.55岁。在这些患者中，大多数为男性，占总数的51.67%。21.67%的患者出现高血糖症，但不到20%的患者患有新发糖尿病。出现高血糖症的个体以高龄为典型特征（P<0.001）。此外，高龄与血糖浓度升高之间存在轻微但具有统计学意义的关联（R=0.254，P<0.001）。性别对高血糖症的发生没有显著影响（P=0.199）。CRP水平与血糖浓度（P=0.524）或高血糖症的发生率（P=0.473）之间没有显著关联。尽管有高血糖症和无高血糖症的个体之间血氧饱和度没有显著差异（P=0.06），但较高的血糖浓度与较低的血氧饱和度相关（R = -0.151，P<0.001）。
考虑到血糖浓度、高龄与疾病严重程度之间的相关性，建议对所有COVID-19患者仔细筛查和监测高血糖症和新发糖尿病。有效管理这些并发症可加强对患者总体预后及后续并发症的控制。
